Radius Health Inc (OQ:RDUS)

Oct 21, 2020 08:15 am ET
Radius Health, Inc.: Progress Since May 2020
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since May 2020. The Company will provide further updates during its third quarter earnings call and at subsequent investor...
Oct 20, 2020 04:15 pm ET
Radius Health to Announce Third Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, November 5, 2020
Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 5, 2020. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and...
Oct 06, 2020 04:30 pm ET
Peter A. Schwartzman Joins Radius Health, Inc.
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that Peter A. Schwartzman is joining the company as Vice President in the newly formed Capital, Strategy and Transactions (CST) Group. Peter, as part of the group, will...
Oct 01, 2020 08:45 am ET
Radius Health Divests RAD 140 Program to Ellipses Pharma
Radius Health, Inc. (Nasdaq: RDUS) announced today that the company has successfully sold its second oncology pipeline asset – RAD 140 - to Ellipses Pharma Limited, completing Radius’s divestment of its oncology assets. Under the agreement,...
Sep 25, 2020 05:51 am ET
Radius Health & Menarini Group Provide Elacestrant Update
WALTHAM, Mass. and FLORENCE, Italy, Sept. 25, 2020 /CNW/ -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial....
Sep 24, 2020 04:15 pm ET
Radius Health & Menarini Group Provide Elacestrant Update
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial. EMERALD Phase 3 Study The target enrollment milestone has been reached in the Phase 3...
Sep 24, 2020 08:15 am ET
Radius Health Provides Business Update
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that Jose (Pepe) Carmona will be stepping down as Chief Financial Officer of Radius Health, Inc., with immediate effect. “Pepe joined Radius one month after the FDA...
Sep 09, 2020 07:45 am ET
Radius Health Announces Scientific Presentations on abaloparatide at ASBMR 2020 Annual Meeting
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American Society for Bone and Mineral Research (ASBMR) 2020 Annual Virtual Meeting which will take place between...
Sep 08, 2020 08:00 am ET
Radius Health: Enrollment Completed for Phase 3 wearABLe trial
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced completion of enrollment in its “wearABLe” phase 3 trial. The study was designed to look at the effects on bone mineral density of abaloparatide delivered via a novel...
Sep 02, 2020 04:15 pm ET
Radius Health to Participate in the Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley Virtual 18th Annual Global Healthcare Conference
Radius Health, Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2020. Radius Health management will host virtual meetings with investors during the Citi 15th Annual BioPharma Virtual...
Aug 25, 2020 09:00 am ET
Radius Health Provides Business Update
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced a business update including the extension of the patent for TYMLOS® as well as the completion of enrollment for its Phase 3 study, which is assessing the safety and...
Aug 10, 2020 08:15 am ET
Radius Health Announces Second Quarter 2020 Operating Results
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the second quarter ended June 30, 2020 and provided a business update. “Completing the elacestrant transaction was...
Aug 10, 2020 08:15 am ET
Sean Murphy joins Radius Health Board of Directors
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect. Sean has several decades of experience in the industry across pharmaceuticals,...
Jul 30, 2020 04:10 pm ET
Guardant Health Announces Collaboration with Radius Health to Develop Liquid Biopsy Companion Diagnostic for Elacestrant
Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Radius Health, Inc. (Radius, Nasdaq: RDUS) to pursue regulatory approval of the Guardant360® CDx as a companion diagnostic for elacestrant (RAD1901), an...
Jul 27, 2020 04:15 pm ET
Radius Health to Announce Second Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Monday, August 10, 2020
Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Monday, August 10, 2020. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and...
Jul 23, 2020 04:15 pm ET
Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant
The Menarini Group and Radius Health, Inc. (Nasdaq: RDUS) announced today that the companies have entered into an exclusive global license agreement for development and commercialization of elacestrant.   Elacestrant is an oral SERD, a selective...
May 27, 2020 05:00 am ET
Pivotal Phase III trial of abaloparatide-SC in Japanese women and men with osteoporosis achieves primary endpoint
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that its partner, Teijin Pharma Limited, has submitted a New Drug Application for abaloparatide-SC in Japan for the treatment of osteoporosis in patients who are at...
May 07, 2020 04:15 pm ET
Radius Health Announces First Quarter 2020 Operating Results
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the first quarter ended March 31, 2020 and provided a business update. “In these challenging and unprecedented times, I am proud...
Apr 28, 2020 04:35 pm ET
Radius Health Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Company’s Board of Directors (the “Board”) granted G. Kelly Martin, in connection with his appointment as Chief Executive Officer and President of the Company,...
Apr 28, 2020 04:30 pm ET
Radius Health Announces CEO Leadership Transition
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that Jesper Hoeiland will step down as President and Chief Executive Officer to return, after many years abroad, to his home country of Denmark. In order to assist with...
Apr 20, 2020 04:15 pm ET
Radius Health to Announce First Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday May 7, 2020
Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Thursday, May 7, 2020. The Company will host a conference call and live audio webcast at 4:45 p.m. ET that day to discuss the results and...
Mar 03, 2020 09:15 am ET
Radius Health to Present at Cowen 40th Annual Healthcare Conference
Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President & CEO and Pepe Carmona, CFO will present a corporate update at the Cowen 40th Annual Healthcare Conference in Boston at 08:40 a.m. ET on Wednesday, March 4, 2020....
Feb 27, 2020 07:30 am ET
Radius Health Announces Fourth Quarter and Full-Year 2019 Operating Results
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the fourth quarter and full-year ended December 31, 2019 and provided a business update. “I am very pleased that TYMLOS exited...
Feb 13, 2020 04:05 pm ET
Radius Health to Announce Fourth Quarter and Full Year 2019 Financial Results, Host Conference Call and Live Webcast on Thursday, February 27, 2020
Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter and full year 2019 financial results on Thursday, February 27, 2020. The Company will host a conference call and live audio webcast at 8:00 a.m. ET that day to...
Feb 13, 2020 04:05 pm ET
Radius Health to Present at 9th Annual SVB Leerink Partners Global Healthcare Conference
Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President & CEO and Pepe Carmona, CFO will present a corporate update at the 9th Annual SVB Leerink Partners Global Healthcare Conference at 10:30 a.m. ET on Thursday,...
Jan 13, 2020 09:00 am ET
Radius Exceeds 2019 Financial Guidance and Provides Business Update at the 38th Annual J.P. Morgan Healthcare Conference
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that it has exceeded its 2019 financial guidance with unaudited full-year TYMLOS® (abaloparatide) injection U.S. net revenue surpassing the upper range of $172 million....
Jan 06, 2020 04:14 pm ET
Radius Health to Present at the 38th Annual J.P. Morgan Healthcare Conference
Radius Health, Inc. (Nasdaq: RDUS), today announced that its senior executive management team will present a corporate update at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 11:30 am PST at the Westin St....
Dec 06, 2019 09:47 am ET
Radius Health Announces Scientific Presentations at 2019 San Antonio Breast Cancer Symposium (SABCS)
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced its scientific presentations on elacestrant and RAD140 at the upcoming 2019 San Antonio Breast Cancer Symposium, which will take place from December 10 – 14 in San...
Dec 02, 2019 04:52 pm ET
Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Compensation Committee of the Company’s Board of Directors granted a new employee an option to purchase 50,000 shares of the Company’s common stock with a per...
Nov 15, 2019 04:15 pm ET
Radius Health to Present at Jefferies 2019 Global Healthcare Conference in London
Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Hoeiland, President and CEO of the Company, will present a corporate update at the Jefferies 2019 Global Healthcare Conference in London, United Kingdom on Wednesday, November 20, 2019...
Nov 05, 2019 04:05 pm ET
Radius Health Announces Third Quarter 2019 Results and Corporate Update
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the third quarter ended September 30, 2019 and provided a strategic business update. Radius remains confident TYMLOS® will...
Oct 23, 2019 05:37 pm ET
Radius Health to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 5, 2019
Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter 2019 financial results on Tuesday, November 5, 2019. The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the results...
Sep 13, 2019 06:03 pm ET
Radius Health to Present Data on Abaloparatide at ASBMR 2019 Annual Meeting
Radius Health, Inc. (Nasdaq: RDUS), today announced it will present five posters, including results from a real-world study on patient experience, at the American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting, which will take...
Sep 03, 2019 09:00 am ET
Radius Health to Participate in the Citi 14th Annual Biotech Conference and Morgan Stanley 17th Annual Global Healthcare Conference in September
Radius Health, Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2019. Radius Health management will host meetings with investors at the Citi 14th Annual Biotech Conference in Boston on September 5,...
Aug 07, 2019 04:01 pm ET
Radius Health Announces Second Quarter 2019 Operating Results
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the second quarter ended June 30, 2019 and provided a business update. “I am delighted to see continued market share...
Aug 05, 2019 04:00 pm ET
Radius Health Initiates Phase 3 wearABLe Study of Abaloparatide-Patch in Postmenopausal Osteoporosis Patients at High Risk for Fracture
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the randomization of the first patient in the Phase 3 wearABLe clinical trial studying the safety and efficacy of abaloparatide-transdermal patch (abaloparatide-patch)...
Jul 23, 2019 09:00 am ET
Radius Health to Announce Second Quarter 2019 Financial Results, Host Conference Call and Live Webcast on Wednesday, August 7, 2019
Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter 2019 financial results on Wednesday, August 7th, 2019. The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the...
Jul 17, 2019 04:52 pm ET
Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Compensation Committee of the Company’s Board of Directors granted a new employee an option to purchase 65,000 shares of the Company’s common stock with a per...
Jun 04, 2019 09:00 am ET
Radius Health to Present at Goldman Sachs 40th Annual Global Healthcare Conference
Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona, Chief Financial Officer and Joe Kelly, Senior Vice President of Sales and Marketing, will present a corporate update at the Goldman Sachs 40th Annual Global Healthcare...
May 10, 2019 04:42 pm ET
Radius Health to Present at Bank of America Merrill Lynch Health Care Conference 2019
Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona, Chief Financial Officer and Joe Kelly, Senior Vice President of Sales and Marketing, will present a corporate update at the Bank of America Merrill Lynch Health Care Conference...
May 08, 2019 07:56 am ET
Radius Health Announces First Quarter 2019 Operating Results
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the first quarter ended March 31, 2019 and provided a business update. “I am very pleased to see continued strong market share...
Apr 23, 2019 09:00 am ET
Radius Health to Announce First Quarter 2019 Financial Results, Host Conference Call and Live Webcast on Wednesday, May 8, 2019
Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter 2019 financial results on Wednesday, May 8, 2019. The Company will host a conference call and live audio webcast at 8:00 a.m. ET that day to discuss the results and...
Apr 17, 2019 08:00 am ET
Radius Health to Present Two Posters at AACE 2019 Annual Meeting
Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it will...
Mar 29, 2019 07:45 am ET
Detailed Research: Economic Perspectives on General Mills, Archrock, Crocs, Monolithic Power, Radius Health, and Gibraltar Industries — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of General Mills, Inc. (NYSE:GIS), Archrock, Inc. (NYSE:AROC), Crocs, Inc....
Mar 23, 2019 12:45 pm ET
Radius Health Presents Analysis from Phase 3 ACTIVE Trial and Data from Preclinical Studies for TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting
Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today presented a...
Mar 18, 2019 08:00 am ET
Radius Health to Present Data on TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting
Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it will...
Mar 11, 2019 04:30 pm ET
Radius Health to Present at Cowen 39th Annual Healthcare Conference
Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at the Cowen 39th Annual Healthcare Conference on Wednesday, March 13, 2019. Information on the presentation...
Mar 01, 2019 09:00 am ET
Radius Health to Participate in 2019 Credit Suisse Global Healthcare Conference
Radius Health, Inc. (Nasdaq: RDUS), today announced that Company management will be attending and participating in the 2019 Credit Suisse Global Healthcare Conference in London on Tuesday, March 5, 2019 and hosting one-on-one meetings with...
Feb 28, 2019 04:05 pm ET
Radius Health Announces Fourth Quarter and Full-Year 2018 Operating Results
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the fourth quarter and full-year ended December 31, 2018 and provided a business update. “I am very pleased with the continued...
Feb 19, 2019 09:00 am ET
Radius Health to Present at Leerink Partners 8th Annual Global Healthcare Conference
Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at the Leerink Partners 8th Annual Global Healthcare Conference on Friday, March 1, 2019. Information on the...
Feb 14, 2019 09:00 am ET
Radius Health to Announce Fourth Quarter and Full Year 2018 Financial Results, Host Conference Call and Live Webcast on Thursday, February 28, 2019
Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019. The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to...
Feb 06, 2019 07:45 am ET
Detailed Research: Economic Perspectives on Edwards Lifesciences, Zimmer Biomet, American Outdoor Brands, Radius Health, Kaman, and FARO Technologies — What Drives Growth in Today's Competitive Landsc
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Edwards Lifesciences Corporation (NYSE:EW), Zimmer Biomet Holdings, Inc....
Jan 25, 2019 09:00 am ET
Radius Health Appoints Jessica Hopfield, Ph.D., to Board of Directors
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and...
Jan 07, 2019 09:22 am ET
Radius Exceeds 2018 Financial Guidance and Provides Business Update at the 37th Annual J.P. Morgan Healthcare Conference
Radius Health, Inc. (Nasdaq: RDUS), today announced that it has exceeded its 2018 financial guidance with full-year TYMLOS® U.S. net sales surpassing the upper range of $95 to $98 million. Radius closed 2018 with a $235 million cash, cash...
Jan 02, 2019 04:15 pm ET
Radius Health to Present at the 37th Annual J.P. Morgan Healthcare Conference
Radius Health, Inc. (Nasdaq: RDUS), today announced that President and Chief Executive Officer, Jesper Høiland, will present a corporate update at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 1:30 pm PST at the...
Dec 06, 2018 08:00 am ET
LogicBio Therapeutics Appoints Richard Moscicki, M.D., and Michael Wyzga to Board of Directors
LogicBio Therapeutics, Inc.  (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the appointment biopharmaceutical industry leaders Richard Moscicki, M.D. and Michael Wyzga to its...
Nov 30, 2018 09:00 am ET
Radius Health Provides Updates on its Oncology Programs and Announces Scientific Presentations at 2018 San Antonio Breast Cancer Symposium (SABCS)
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced updates from its oncology pipeline and its scientific presentations on elacestrant and RAD140 at the upcoming 2018 San Antonio Breast Cancer Symposium. The Company’s...
Nov 07, 2018 07:25 am ET
Recent Analysis Shows InterDigital, Alpha and Omega Semiconductor, Alliance Resource Partners, Aircastle, XPO Logistics, and Radius Health Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of InterDigital, Inc. (NASDAQ:IDCC), Alpha and Omega Semiconductor Limited...
Nov 01, 2018 07:40 am ET
Radius Health Announces Third Quarter 2018 Operating Results and Financial Guidance for FY 2018 and FY 2019
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today reported its financial and operating results for the third quarter ended September 30, 2018 and provided a business update. “I am very pleased with the continued strong...
Oct 12, 2018 09:00 am ET
Radius Health to Announce Third Quarter 2018 Financial Results, Host Conference Call and Live Webcast on November 1, 2018
Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 1, 2018. The Company will host a conference call and live audio webcast at 8:00 a.m. ET that day to discuss the results and...
Oct 09, 2018 08:25 am ET
Report: Exploring Fundamental Drivers Behind Skyworks Solutions, Radius Health, Novanta, Flowers Foods, Rexford Industrial Realty, and Donaldson — New Horizons, Emerging Trends, and Upcoming Developme
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Skyworks Solutions, Inc. (NASDAQ:SWKS), Radius Health, Inc....
Oct 03, 2018 07:52 am ET
Radius Health Announces Latest 2019 Medicare Part D Coverage for TYMLOS® (abaloparatide) Injection
Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced the...
Sep 28, 2018 08:30 am ET
Radius Health to Present at the Leerink Partners Oncology Roundtable Series
Radius Health, Inc. (Nasdaq: RDUS) announced today that Jesper Høiland, President and CEO and Charles Morris, Chief Medical Officer of the Company will present a corporate update at the Leerink Partners Oncology Roundtable Series on Wednesday,...
Sep 24, 2018 08:00 am ET
Radius Health to Present Data on Abaloparatide at ASBMR 2018 Annual Meeting
Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it will present...
Sep 11, 2018 09:15 am ET
Radius Health to Present at the Morgan Stanley 16th Annual Global Health Care Conference
Radius Health, Inc. (Nasdaq: RDUS) announced today that Jesper Høiland, President and CEO, and Pepe Carmona, Chief Financial Officer of the Company, will present a corporate update at the Morgan Stanley 16th Annual Global Health Care Conference on...
Sep 06, 2018 04:15 pm ET
Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Company’s Board of Directors granted Dr. Charles Morris, in connection with his appointment as the Company’s Chief Medical Officer, an option to purchase 130,000...
Sep 04, 2018 09:15 am ET
Radius Health Appoints Dr. Charles Morris as Chief Medical Officer
Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced the appointment of Dr. Charles Morris as Chief Medical Officer. Dr. Morris will oversee and lead all clinical development, regulatory and medical affairs strategies and...
Sep 04, 2018 08:00 am ET
BioXcel Therapeutics Appoints Dr. David C. Hanley as Vice President and Head of Global Pharmaceutical Development and Operations
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced the...
Aug 07, 2018 07:45 am ET
Radius Health Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the second quarter ended June 30, 2018 and provided a business update. “We are very pleased to report our continued progress in increasing...
Aug 01, 2018 07:30 am ET
New Research Coverage Highlights Ladder Capital, Gibraltar Industries, Norwegian Cruise Line, Wolverine World Wide, Catalyst Pharmaceuticals, and Radius Health — Consolidated Revenues, Company Growth,
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ladder Capital Corp (NYSE:LADR), Gibraltar Industries, Inc. (NASDAQ:ROCK),...
Jul 24, 2018 04:15 pm ET
Radius Health Provides Update on Appeal of CHMP Opinion for Abaloparatide-SC
Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced that...
Jul 23, 2018 04:44 pm ET
Radius Health to Announce Second Quarter 2018 Financial Results, Host Conference Call and Live Webcast on August 7, 2018
Radius Health (Nasdaq:RDUS) announced today that it will release its second quarter financial results on Tuesday, August 7, 2018. The Company will host a conference call and live audio webcast at 8:00 a.m. ET that day to discuss the results and...
Jul 16, 2018 07:28 pm ET
Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Compensation Committee of the Company’s Board of Directors granted Chhaya Shah, in connection with her appointment as the Company’s Senior Vice President,...
Jul 16, 2018 08:00 am ET
Radius Health Strengthens Senior Management Team with Appointment of Chhaya Shah as Senior Vice President of Technical Operations
Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Chhaya Shah as Senior Vice President of Technical Operations. "Ms. Shah will help strengthen and expand our technical operations infrastructure,...
Jun 07, 2018 08:30 am ET
Radius Health to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and Chief Executive Officer and Pepe Carmona, Senior Vice President and Chief Financial Officer of the Company, will present a corporate update at the at the Goldman...
Jun 05, 2018 08:30 am ET
Radius to Host Investor Day on June 8, 2018
Radius Health, Inc. (Nasdaq:RDUS) announced today that it will host an Investor Day on Friday, June 8, 2018 in New York City starting at 8:00 a.m. ET. Members of the Radius leadership team will provide business updates and facilitate discussions...
May 11, 2018 08:09 pm ET
Radius Health to Present at the Bank of America Merrill Lynch 2018 Annual Healthcare Conference
Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and Chief Executive officer and Pepe Carmona, Senior Vice President and Chief Financial Officer of the Company, will present a corporate update at the Bank of America...
May 10, 2018 07:30 am ET
Radius Health Reports First Quarter 2018 Financial and Operating Results and Provides Business Update
Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS), today reported its financial results for the first quarter ended March 31, 2018 and provided a business update. “The Company’s first quarter results highlight the strong...
Apr 24, 2018 08:00 am ET
Radius Health to Announce First Quarter 2018 Financial Results, Host Conference Call and Live Webcast on May 10, 2018
WALTHAM, Mass., April 24, 2018 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its first quarter financial results on Thursday, May 10, 2018. The Company will host a conference call and live audio webcast...
Apr 20, 2018 08:10 am ET
Report: Developing Opportunities within Clean Energy Fuels, Catalyst Pharmaceuticals, Qorvo, Brunswick, DCT Industrial Trust, and Radius Health — Future Expectations, Projections Moving into 2018
NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clean Energy Fuels Corp. (NASDAQ:CLNE), Catalyst...
Mar 30, 2018 02:32 pm ET
Radius Health Initiates Phase 3 Clinical Trial of Abaloparatide Injection for the Treatment of Male Osteoporosis
Bridging study will evaluate change in spine bone mineral density (BMD) at 12 months compared with placebo
Mar 22, 2018 09:00 am ET
Radius Health Provides Update on CHMP Opinion for Abaloparatide-SC
WALTHAM, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced that...
Mar 17, 2018 12:30 pm ET
Radius Health Presents Positive Data for the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection at ENDO 2018 Annual Meeting
WALTHAM, Mass., March 17, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today presented results...
Mar 12, 2018 04:30 pm ET
Radius Health to Present at ENDO 2018 Including Results of the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection
WALTHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced two presentations...
Mar 06, 2018 08:01 am ET
Radius Health to Present at the Cowen 38th Annual Health Care Conference
WALTHAM, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and CEO of the Company, will present a corporate update at Cowen’s 38th Annual Health Care Conference on Monday, March...
Mar 01, 2018 04:01 pm ET
Radius Health Reports Fourth Quarter and Full Year 2017 Financial and Operating Results and Provides Business Update
TYMLOS™ sales show accelerating market share growth, capturing approximately 32% of osteoporosis patients new to anabolic therapy
Feb 14, 2018 08:00 am ET
Radius Health to Announce Fourth Quarter and Full Year 2017 Financial Results, Host Conference Call and Live Webcast on March 1, 2018
WALTHAM, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2017 financial results on Thursday, March 1, 2018. The Company will host a conference...
Feb 14, 2018 08:00 am ET
Radius Health to Present at 2018 RBC Capital Markets Global Healthcare Conference
WALTHAM, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and CEO of the Company, will present a corporate update at the 2018 RBC Capital Markets Global Healthcare Conference on...
Feb 14, 2018 07:45 am ET
Analysis: Positioning to Benefit within First Data, Target, Kellogg, Builders FirstSource, HD Supply, and Radius Health — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of First Data Corporation (NYSE:FDC), Target Corporation...
Feb 08, 2018 08:00 am ET
Radius Health to Present at Leerink Partners 7th Annual Global Healthcare Conference
WALTHAM, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced...
Jan 05, 2018 09:07 am ET
Radius Health to Present at the 36th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), today announced that President and Chief Executive Officer, Jesper Høiland, will present a corporate update at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January...
Jan 02, 2018 08:05 am ET
Radius Health Welcomes Elhan Webb as Head of Investor Relations and External Communications
WALTHAM, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) announced today that Elhan Webb has joined the Company as Head of Investor Relations and External Communications.
Dec 15, 2017 07:31 am ET
Dec 11, 2017 01:30 pm ET
Fractured Truth Campaign Wins Bronze Pearl Award for Content Marketing Excellence in the Healthcare/Pharmaceutical Industry
WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) today announced that Fractured Truth—an unbranded patient campaign aimed to educate younger postmenopausal women about risks associated with osteoporosis—won the Bronze Healthcare/Pharmaceutical Industry Pearl Award at...
Dec 07, 2017 06:30 pm ET
Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
-Elacestrant 400mg single agent Objective Response Rate (ORR) was 27.3% in heavily pre-treated patients with advanced ER+ breast cancer at the pre-determined study cutoff date of October 30, 2017-
Dec 04, 2017 09:05 am ET
Radius Health Announces Five Presentations on elacestrant (RAD1901) at the San Antonio Breast Cancer Symposium (SABCS)
SABCS to include five abstracts from the development program for elacestrant as a potential treatment of ER-positive advanced breast cancer
Nov 30, 2017 08:00 am ET
New Research: Key Drivers of Growth for First Data, Target, Kellogg, Builders FirstSource, HD Supply, and Radius Health — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of First Data Corporation (NYSE:FDC), Target Corporation...
Nov 27, 2017 04:35 pm ET
Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that its Board of Directors granted Joseph Kelly, in connection with his appointment as the Company’s Senior Vice President of...
Nov 27, 2017 04:05 pm ET
Radius Health Announces Commercial Leadership Changes with Appointment of Joseph Kelly as Senior Vice President of Sales and Marketing, and Promotion of Amanda Mott to Senior Vice President of Market
WALTHAM, Mass., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Joseph Kelly as Senior Vice President of Sales and Marketing, and the promotion of Amanda Mott to...
Nov 02, 2017 04:01 pm ET
Radius Health Reports Third Quarter 2017 Financial and Operating Results and Provides Business Update
First full quarter of TYMLOS™ sales shows accelerating market share & stabilization of the anabolic market
Oct 09, 2017 09:00 am ET
Radius Health to Announce Third Quarter 2017 Financial Results, Host Conference Call and Live Webcast on November 2, 2017
WALTHAM, Mass., Oct. 09, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2017 financial results on Thursday, November 2, 2017. The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the results and provide a company update....
Sep 10, 2017 01:30 pm ET
Radius Health Presents Positive Data for TYMLOS™ (abaloparatide) Injection from the ACTIVExtend Trial at ASBMR 2017 Annual Meeting
ACTIVExtend trial demonstrated statistically significant fracture risk reduction through the 3.5 years of sequential therapy: TYMLOS followed by alendronate...
Jul 21, 2017 04:05 pm ET
Radius Health Announces that the Committee for Medicinal Products for Human Use (CHMP) Has Issued a Second Day-180 List of Outstanding Issues in its Regulatory Review of Eladynos™ (Abaloparatide-SC),
WALTHAM, Mass., July 21, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that on July 21, 2017 the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), issued a second Day-180 List of Outstanding Issues and requested additional data analyses related to the safety and efficacy of abaloparatide-SC in the ...
Jul 13, 2017 07:39 am ET
Radius Health Announces License and Development Agreement for Abaloparatide-SC with Teijin Limited in Japan
Teijin granted a right of reference to Radius regulatory data and use of Radius Intellectual Property for development, manufacture and commercialization of abaloparatide-SC for Japan, the largest market globally for bone anabolics.Radius to receive upfront and milestone payments, royalties, and an option for co-promotion. WALTHAM, Mass., July 13, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius”) (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology ...
Jun 04, 2017 09:00 am ET
Radius Presents Positive Data From A Fully Enrolled Ongoing Phase I Study for Investigational Drug Elacestrant (RAD1901) at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)
-Elacestrant single agent Objective Response Rate (ORR) was 23% in heavily pre-treated patients with advanced ER+ breast cancer at the cut off date of April 28, 2017-...
May 24, 2017 04:00 pm ET
Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS™ in Postmenopausal Women with Osteoporosis
ACTIVExtend trial demonstrated sustained statistically significant fracture risk reduction through the 3.5 years of sequential therapy: TYMLOS followed by an antiresorptive  ...
May 15, 2017 04:15 pm ET
Radius Health Announces New Employment Inducement Grant
WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that on May 15, 2017, the Company's Board of Directors granted Jose (Pepe) Carmona, the Company’s Chief Financial Officer, an option to purchase 125,000 shares of the Company's common stock with a per share exercise price of $34.96, the closing trading price of the Company’s common stock on the N...
May 04, 2017 01:45 pm ET
May 01, 2017 06:30 am ET
Radius Health Reports First Quarter 2017 Financial and Operating Results
US FDA approves TYMLOS™ (abaloparatide) on April 28, 2017, first new bone builder in nearly 15 years...
Feb 23, 2017 04:01 pm ET
Jan 31, 2017 07:00 am ET
Radius Health to Announce Fourth Quarter and Full Year 2016 Financial Results, Host Conference Call and Live Webcast on February 23, 2017
WALTHAM, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2016 financial results on Thursday, February 23, 2017....
Dec 08, 2016 08:45 am ET
Radius Presents Positive Phase I Data for Investigational Drug RAD1901 at the San Antonio Breast Cancer Symposium (SABCS) 2016
 -3 patients had confirmed partial responses by RECIST criteria from ongoing Phase I studies with RAD1901 in patients with advanced estrogen receptor positive breast cancer-...
Nov 01, 2016 06:18 pm ET
Radius Health to Present at the Credit Suisse 25th Annual Healthcare Conference
WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the Credit Suisse 25th Annual Healthcare Conference in Scottsdale, AZ on Monday, November 7, 2016 at 11:00 a.m. Pacific Time/2:00 p.m. Eastern Time....
Oct 12, 2016 07:00 am ET
Radius Health to Announce Third Quarter 2016 Financial Results, Host Conference Call and Live Webcast on November 3, 2016
WALTHAM, Mass., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2016 financial results on Thursday, November 3, 2016....
Sep 19, 2016 01:00 pm ET
Sep 18, 2016 07:30 am ET
Radius Announces Publication of Additional Positive Results from the Phase 3 ACTIVE Trial of Abaloparatide-SC in JBMR
WALTHAM, Mass., Sept. 18, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that additional positive results from the Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial were published in the Journal of Bone and Mineral Research (JBMR).  ...
Aug 30, 2016 07:00 am ET
Radius Health Announces Three Presentations on RAD1901 at the San Antonio Breast Cancer Symposium (SABCS) December 6-10, 2016
WALTHAM, Mass., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced today that it will present new data from multiple studies of RAD1901, an oral selective estrogen degrader, in ER-positive breast cancer at the San Antonio Breast Cancer Symposium Meeting December 6-10, 2016 at the Henry B. Gonzalez Convention Center in San Antonio, Texas....
Aug 16, 2016 11:01 am ET
JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women With Osteoporosis
WALTHAM, Mass., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and other endocrine diseases, today announced that positive results from the Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial were published in the Journal of the American Medical Association (JAMA). This landmark trial enrolled 2,463 patients to evaluate the safety and efficacy of investigational drug abaloparatide for the treatment of postme...
Aug 15, 2016 10:31 am ET
Learn how to target a 20% return on Valeant Pharmaceuticals, or get option-trade ideas on Acacia Communications, Radius Health, General Electric and Exelixis or any stock you choose
CHICAGO, Aug. 15, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACIA, EXEL, GE, RDUS, and VRX....
Aug 04, 2016 06:30 am ET
Radius Health Reports Second Quarter 2016 Financial and Operating Results
Radius’ NDA for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis was accepted for filing by FDA with a PDUFA date of March 30, 2017...
Aug 02, 2016 11:51 am ET
Radius Health to Present at the 36th Annual Canaccord Genuity Growth Conference
WALTHAM, Mass., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the 36th Annual Canaccord Genuity Growth Conference on August 10, 2016 at 4:00 pm EDT at the InterContinental Hotel in Boston, MA....
Jul 20, 2016 04:19 pm ET
Radius Health Announces Multiple Presentations at the American Society for Bone and Mineral Research 2016 Annual Meeting September 16-19, 2016
WALTHAM, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced today that it will present new data from multiple studies of abaloparatide in women with postmenopausal osteoporosis at the American Society for Bone and Mineral Research (ASBMR) 2016 Annual Meeting, September 16-19, 2016, at the Georgia World Congress Center in Atlanta, Georgia....
Jul 15, 2016 11:36 am ET
Radius Health to Announce Second Quarter 2016 Financial Results, Host Conference Call and Live Webcast on August 4, 2016
WALTHAM, Mass., July 15, 2016 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its second quarter 2016 financial results on Thursday, August 4, 2016....
Jul 05, 2016 07:00 am ET
Radius Health to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
WALTHAM, Mass., July 05, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that Chief Commercial Officer, David Snow, will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12, 2016 at 1:00 p.m. EDT at Le Parker Meridien Hotel in New York, NY....
Jun 01, 2016 12:06 pm ET
Radius Health to Present at the Goldman Sachs Thirty-Seventh Annual 2016 Healthcare Conference
WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the Goldman Sachs Thirty-Seventh Annual Global Healthcare Conference on June 7, 2016 at 3:20 p.m. PDT at the Terranea Resort in Rancho Palos Verdes, California....
May 31, 2016 02:00 pm ET
Radius Announces FDA Acceptance for Filing of New Drug Application for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis
WALTHAM, Mass., May 31, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that its New Drug Application (NDA) for abaloparatide–SC has been accepted for filing by the U.S. Food and Drug Administration (FDA).  The acceptance of the NDA reflects the FDA’s determination that the application is sufficiently complete to permit a substantive review....
May 13, 2016 04:30 pm ET
Radius Health Announces New Employment Inducement Grants
WALTHAM, Mass., May 13, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that, on May 8, 2016, the compensation committee of the company's board of directors granted six new non-executive employees options to purchase an aggregate of 52,550 shares of the company's common stock with a per share exercise price of $30.93, the closing trading price of the company’s common stock on the NASDAQ Global Market on Friday, May 6...
May 05, 2016 06:30 am ET
Radius Health Reports First Quarter 2016 Financial and Operating Results
Radius submitted an NDA to the US FDA for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis and reduction of fracture risk....
May 02, 2016 11:45 am ET
Radius Health to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
WALTHAM, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Tuesday, May 10, 2016 at 5:00 pm PT at the Encore at the Wynn, Las Vegas, NV....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.